Yuting Sun, Ph.D.
Affiliations: | 2009 | University of Illinois, Urbana-Champaign, Urbana-Champaign, IL |
Google:
"Yuting Sun"Parents
Sign in to add mentor| Andrew Belmont | grad student | 2009 | UIUC | |
| (Mechanisms of mTOR signal transduction regulating cell growth and differentiation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sun Y, Meyers BA, Czako B, et al. (2020) Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms towards osimertinib. Cancer Research |
| Zhang L, Yao Y, Zhang S, et al. (2019) Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Science Translational Medicine. 11 |
| Echeverria GV, Ge Z, Seth S, et al. (2019) Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Science Translational Medicine. 11 |
| Sun Y, Bandi M, Lofton T, et al. (2019) Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation. Cell Reports. 26: 469-482.e5 |
| Echeverria G, Ge Z, Seth S, et al. (2019) Abstract GS5-05: Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state Cancer Research. 79 |
| Sun Y, Meyers BA, Johnson SB, et al. (2019) Abstract C036: Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance Molecular Cancer Therapeutics. 18 |
| Molina JR, Sun Y, Protopopova M, et al. (2018) An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nature Medicine |
| Lissanu Deribe Y, Sun Y, Terranova C, et al. (2018) Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nature Medicine |
| Zhang L, Zhang H, Guo H, et al. (2018) A Novel Patient-Derived Xenograft Model of Secondary CD20- CNS Lymphoma for Mechanistic and Therapeutic Exploration Blood. 132: 1669-1669 |
| Marszalek JR, Seth S, Corti D, et al. (2018) Abstract 2856: Targeting OXPHOS with IACS-010759 to eliminate standard of care resistant tumor cells Cancer Research. 78: 2856-2856 |